BBSRC Networks help Holiferm turn greentech breakthrough into growing business
University of Manchester spinout Holiferm is justifiably upbeat about the future. Its novel method for making a key ingredient of everyday household products avoids fossil fuel-based feedstocks. The resulting ingredient is both biodegradable and low in ecotoxicity – opening pathways to major global markets. It’s taken just eight years to get here, driven by the energy and ingenuity of PhD student Ben Dolman and his supervisor Dr James Winterburn. BBSRC Networks in Industrial Biotechnology and Bioenergy (NIBB) helped them develop contacts that proved crucial to this classic clean-growth success story, which now includes a strategic agreement with one of the world’s biggest chemical producers.
- Innovative lower-cost process for turning renewable feedstocks into biodegradable surfactants successfully brought to market.
- The NIBB provided targeted support at critical points in the emergence of Holiferm, the spinout created from the breakthrough.
- Over £1 million of investment already secured in the company.
- Rapidly growing workforce, with 14 full-time equivalent (FTE) jobs and rising at the Manchester/Daresbury-based firm.
- Holiferm set to reach industrial-scale production capacity in 2022, providing a significant, environmentally friendly boost to decarbonisation of the chemicals sector.
Full story can be found on BBSRC website https://bbsrc.ukri.org/research/impact/bbsrc-networks-help-holiferm-turn-greentech-breakthrough-into-growing-business/
ESACT-UK 2021 – Registration open – FREE to attend
Registration is now open for the 31st ESACT UK annual conference taking place virtually on 6/7 January and is FREE for all members HERE
Programme includes presentations on topics such as Covid-19 & vaccine manufacture, antibody bioprocessing and advanced therapies. Speakers include –
Paul Kellam, Kymab Ltd
Sandy Douglas, University of Oxford
Martin Smith, VMIC
Felicity Rose, University of Nottingham
James Budge, University of Kent
Ivan Wall, Aston University
John Pieracci, Biogen
BioProNET2, 7th Annual Scientific Meeting
November 19/20 2020
This years’ symposium will be virtual, covering the entire range of production and manufacture of biological modalities (expression-process-analytics). Presentations will be delivered in short sessions, starting on the afternoon of November 19th and throughout November 20th. A short poster session will run on November 20th.
The meeting is free to attend and you can register HERE
Thursday November 19th
Bioprocessing perspectives for COVID-19 (14.00- 15:50)
- Antu Dey (IAVI)
- Paul Davis (Mologic Ltd)
- Robin Shattock (Imperial College London)
- Simon Carding (Quadram Institute)
Friday November 20th
Good analytics make or break the process (09.30- 11:00)
- Marc Olivier Baradez (Cell & Gene Therapy Catapult)
- Liz Topp (NIBRT/Purdue)
- James Wilkinson (Refeyn Ltd)
Poster session (11:00-12:00)
Full list HERE
The process quality defines the product (12:45- 14:00)
- Anurag Rathore (IIT Delhi)
- Tibor Nagy (Fujifilm Diosynth) Biosynthologies)
- Franscesc Godia (UAB, Barcelona)
Engineering cell factories to make products – (14:45-16:20)
- Govind Rao (University of Maryland)
- Mike Jewett (Northwestern University, Illinois)
- Velia Siciliano (IIT, Genova)
- Laura Segatori (Rice University, Texas)
BioProNET2 is an academic-industry networking club sponsored by industry, who together with a group of academics aim to maintain and develop the community that was brought together so successfully by BioProNET.
BioProNET2 Steering Group:Paul Dalby (UCL), Alan Dickson (University of Manchester), Jo Flannelly (University of Manchester), Cleo Kontoravdi (Imperial College), Mark Smales (University of Kent), Ivan Wall (Aston University).
The steering group includes representatives of Allergan Biologics, AZ, Cell & Gene Therapy Catapult, Cobra Biologics, Fujifilm Diosynth Biotechnologies, GSK, Kymab, Lonza Biologics, Pall Corporation.
Welcome to BioProNET2 – Academic – Industry Network
BioProNET has evolved and returned as BioProNET2, an academic-industry networking club with sponsorship through a group of industrial and commercial colleagues who together with a group of academics (see below) aim to maintain and develop the community that was brought together so successfully by BioProNET. Our general objectives are to:
- mobilise a collaborative UK scientific community to address the challenges around, and enhance, the manufacture of emerging novel biological modalities.
- capitalise on entrepreneurship and address fundamental scientific challenges to enable robust and economically viable manufacture.
- develop a forum to engage academics and early career researchers with the industrial sector and entrepreneurial practitioners to provide a framework to train and inspire the next generation.
As a starting point for the focus of BioProNET2 we will be running an annual scientific meeting and a series of subject-specific workshops throughout each year, which this year will have a virtual, on-line structure. You have previously been associated with, and/or attended, meetings organised by BioProNET and, at this stage, we wish to inform you of our general plans and ask you to indicate your interest in hearing about, and being involved in, future activities organised by BioProNET2. We hope that you will and would ask you to forward this communication to any colleagues who you would also think would be interested in being part of BioProNET2 activities.
Just insert the appropriate heading and return this e-mail to the sending address:
YES, please!! Let me know all about BioProNET2 activities
NO, thank you, this is no longer appropriate for me
We are currently updating our BioProNET2 website so please check HERE and our Twitter feed for further information or please contact Jo Flannelly
BioProNET2 Steering Group:
Paul Dalby (UCL), Alan Dickson (University of Manchester), Jo Flannelly (University of Manchester), Cleo Kontoravdi (Imperial College), Mark Smales (University of Kent), Ivan Wall (Aston University).
Current industrialists include representatives of Allergan Biologics, AZ, Cell & Gene Therapy Catapult, Cobra Biologics, Fujifilm Diosynth Biotechnologies, GSK, Kymab, Lonza Biologics, Pall Corporation.
You might also be interested in the BBSRC phase II NIBB.
Case studies of how our funding and events has brought together members from academia and industry to work on innovative research can be found here.
Read our interim achievement report
Member Profiles – read how BioProNET has helped members Charlie and Michael.
Newsletters & reports
Photos from BioProNET’s 2017 Science Meeting, taken by Linas Tamosaitis